RT Journal Article
SR Electronic
T1 Novel Terpenoid-Type Quinones Isolated from<em>Pycnanthus angolensis</em> of Potential Utility in the Treatment of Type 2 Diabetes
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 529
OP 534
VO 288
IS 2
A1 Jian Luo
A1 Jeanne Cheung
A1 Eileen M. Yevich
A1 John P. Clark
A1 Joyce Tsai
A1 Priscilla Lapresca
A1 Rosa P. Ubillas
A1 Diana M. Fort
A1 Thomas J, Carlson
A1 Richard F. Hector
A1 Steven R. King
A1 Christopher D. Mendez
A1 S. D. Jolad
A1 Gerald M. Reaven
YR 1999
UL http://jpet.aspetjournals.org/content/288/2/529.abstract
AB Using an ethnomedical-based drug discovery program, two previously unknown compounds (SP-18904 and SP-18905) from Pycnanthus angolensis were isolated that lower glucose concentrations in mouse models of type 2 diabetes. SP-18904 and SP-18905 are terpenoid-type quinones that significantly lowered plasma glucose concentration (p &lt; .05) when given orally to either ob/ob or db/db mice, both of which are hyperglycemic and hyperinsulinemic. The antihyperglycemic actions of SP-18904 and SP-18905 were associated with significant decreases in plasma insulin concentrations (p &lt; .05), suggesting that both compounds lowered glucose by enhancing insulin-mediated glucose uptake. This was supported by the insulin suppression test in ob/ob mice. Studies in hyperglycemic, insulin-deficient mice and in vitro experiments on 3T3-L1 adipocytes further supported this conclusion. As such, these two terpenoid-type quinones represent a new class of compounds of potential use in the treatment of type 2 diabetes. The American Society for Pharmacology and Experimental Therapeutics